(Q42681037)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26952941%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

title

Combined treatment with reboxetine in depressed patients with no response to venlafaxine: a 6-week follow-up study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26952941%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26952941%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Antonio Pardo

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26952941%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

author name string

Cecilio Álamo

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26952941%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Francisco López-Muñoz

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26952941%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Pilar García-García

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26952941%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

publication date

1 October 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26952941%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

published in

Acta Neuropsychiatrica

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26952941%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

volume

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26952941%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26952941%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

page(s)

291-296

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26952941%20AND%20SRC:MED&resulttype=core&format=json

Venlafaxine in treatment-resistant major depression: a Canadian multicenter, open-label trial.

10 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1601-5215.2007.00187.X

Combining Antidepressants for Treatment-Resistant Depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1601-5215.2007.00187.X

To combine or not to combine? A literature review of antidepressant combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1601-5215.2007.00187.X

Efficacy and tolerability of reboxetine in depressive patients treated in routine clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1601-5215.2007.00187.X

Isoniazid-induced psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1601-5215.2007.00187.X

Venlafaxine. A review of its pharmacology and therapeutic potential in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1601-5215.2007.00187.X

Efficacy of venlafaxine in depressive illness in general practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1601-5215.2007.00187.X

Clinical pharmacokinetics of reboxetine, a selective norepinephrine reuptake inhibitor for the treatment of patients with depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1601-5215.2007.00187.X

Combined antidepressants: clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1601-5215.2007.00187.X

Treatment algorithms in treatment-resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1601-5215.2007.00187.X

Double-blind, placebo-controlled study with reboxetine in inpatients with severe major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1601-5215.2007.00187.X

The prevalence and distribution of major depression in a national community sample: the National Comorbidity Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1601-5215.2007.00187.X

Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive offsodes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1601-5215.2007.00187.X

Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1601-5215.2007.00187.X

Lithium augmentation of venlafaxine: an open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1601-5215.2007.00187.X

Reboxetine adjunct for partial or nonresponders to antidepressant treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1601-5215.2007.00187.X

Selective serotonin reuptake inhibitors combined with venlafaxine in depressed patients who had partial response to venlafaxine: four cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1601-5215.2007.00187.X

Use of bupropion in combination with serotonin reuptake inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1601-5215.2007.00187.X

10.1111/J.1601-5215.2007.00187.X

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26952941%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

1 reference